英夫利昔治疗克罗恩病疗效与安全性的meta分析

Efficacy of infliximab in the treatment of Crohn's disease:A meta analysis

[目的]通过运用meta分析,系统评价英夫利昔单抗治疗克罗恩病(CD)的疗效和安全性。[方法]通过检索中国期刊全文数据库、中国生物医学文献数据库、cochrane图书馆、Pubmed和西文生物医学数据库(EMCC)获取文献,纳入所有应用英夫利昔治疗CD的随机对照试验(randomized controlled trials,RCTs)。根据Jadad评分评价纳入文献的质量。2位作者独立提取资料并进行质量评价。对纳入文献采用固定效应模型进行meta分析,通过固定效应模型和随机效应模型分析比较的方法进行敏感性分析。[结果]共5个RCTs试验符合纳入标准,用于此次meta分析。Meta分析显示:①临床缓解:英夫利息单抗治疗CD的缓解率较安慰剂高;②临床应答:英夫利息单抗治疗CD的临床应答率高于安慰剂;③不良反应:英夫利西单抗治疗CD不良反应的发生率与安慰剂相比无明显差异;④复发率:英夫利息单抗治疗存在瘘管CD的复发率与安慰剂相比无明显差异。[结论]英夫利西单抗治疗CD具有一定疗效。

[Objective]To evaluate the efficacy of infliximab quantitatively in the treatment of Crohn＇s disease（CD） by meta-analysis. [Methods] Electronic searches including Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Pubrned and EMCC were conducted to identify randomized con- trolled trials with infliximab in the treatment of CD. Methodological quality of trims was assessed according to Jadad scale. Data extraction and assessment of methodological quality of each study were independently performed by two reviewers. Meta analysis was employed with a fixed-effects model, and conduct saensitivity analysis. [Results]Five randomized controlled trials of infliximab therapy in CD, and were included in this meta-analysis. The meta-analysis results showed that ： ①Clinical remission： the response rate of clinical re- mission with infliximab was higher. ②Clinical response：the rate of clinical response with the treatment of infliximab was higher compared to the placebo. ③Adverse effects： there were not significant differences in in- fliximab versus placebo. ④ Fistula recurrence： the fistula recurrence rate of Crohn＇ s disease was no significant difference compared with placebo. [Conclusion]Infliximab treatment of Crohn＇s disease have a certain effect.